Home › NDC Lookup › RxCUI directory › RxCUI 1804760

Agalsidase beta 5 MG Injection — RxCUI 1804760

Name: Agalsidase beta 5 MG Injection (RxCUI 1804760)
Creator: Brian Staiger, PharmD

RxNorm drug concept · Semantic clinical drug

RxCUI 1804760 Semantic clinical drug · SCD ● Current RxNorm concept 2 FDA products 2 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by Dr. Brian Staiger, PharmD

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI1804760

Official nameAgalsidase beta 5 MG Injection

Concept typeSemantic clinical drug (SCD)

RxNorm statusCurrent RxNorm concept

FDA products mapped2

Package NDCs mapped2

Reported Medicaid activity (SDUD)3,038 prescriptions · 28 state & territory Medicaid programs · latest period Q4 2025

RxNorm release07/06/2026

Snapshot dataJul 14, 2026

🕸️ Concept Web — How Agalsidase beta 5 MG Injection Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.

This page's concept Agalsidase beta 5 MG Injection RxCUI 1804760 Semantic clinical drug · SCD

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

Ingredients 1

The active substance itself — no strength, form, or brand attached yet.
- Agalsidase beta 338817 IN
Brand names 1

The same medicine's trade names. A brand name alone says nothing about strength or form.
- Fabrazyme 338818 BN
Dose forms 6

The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.
- Agalsidase beta Injection 1804754 SCDF
- Agalsidase beta Injectable Product 1164257 SCDG
- Agalsidase beta Injection [Fabrazyme] 1804757 SBDF
- Fabrazyme Injectable Product 1174662 SBDG
- Injection 1649574 DF
- Injectable Product 1151126 DFG
Clinical & branded drugs 3

Ingredient + strength + dose form. These are the concepts real FDA products actually carry.
- Agalsidase beta 5 MG 1804759 SCDC
- Agalsidase beta 5 MG Injection [Fabrazyme] 1804762 SBD
- Agalsidase beta 5 MG [Fabrazyme] 1804761 SBDC

Showing up to 8 concepts per family — 11 of 11 stored related concepts drawn.

These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

Agalsidase beta 5 MG SCDC · 1804759
Agalsidase beta Injection SCDF · 1804754
Agalsidase beta Injectable Product SCDG · 1164257

Brand-Name Concepts

Agalsidase beta 5 MG Injection [Fabrazyme] SBD · 1804762
Agalsidase beta 5 MG [Fabrazyme] SBDC · 1804761
Agalsidase beta Injection [Fabrazyme] SBDF · 1804757
Fabrazyme Injectable Product SBDG · 1174662
Fabrazyme BN · 338818

📦 FDA Products & Package NDCs

2 products · 2 package NDCs

2 package NDCs map to RxCUI 1804760 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.

Package NDC	Package	Brand / generic name	Labeler	Marketing start
58468-0040-01	1 VIAL, GLASS in 1 CARTON (58468-0040-1) / 7 mL in 1 VIAL,...	Fabrazyme	Genzyme Corporation	2008-12-17
58468-0041-01	1 VIAL, GLASS in 1 CARTON (58468-0041-1) / 1 mL in 1 VIAL,...	Fabrazyme	Genzyme Corporation	2008-12-17

Observed labelers: Genzyme Corporation (2) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🧾 Billing Codes (HCPCS)

Medical billing codes (HCPCS "J-codes") that connect to this concept's packages — used mostly when a clinic or hospital bills for a drug it administers. Each code links to its full billing page.

Code	Descriptor	Mapped packages	Sources
J0180	Agalsidase beta injection	2	CMS

⚠ A crosswalk is not coverage: an NDC↔HCPCS mapping does not guarantee any payer covers or pays the code. Always verify the current payer policy before billing.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7

openFDA export observedJul 14, 2026

RxNorm release07/06/2026

Methodology2026-07-full-catalog-v1

A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.

This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.